<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003184</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066010</org_study_id>
    <secondary_id>PPMC-IRB-94-78</secondary_id>
    <secondary_id>OCC-ONC-9408-L</secondary_id>
    <secondary_id>NCI-V98-1379</secondary_id>
    <nct_id>NCT00003184</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Women With Metastatic Breast Cancer</brief_title>
  <official_title>Phase I Trial Using a CD80-Modified Allogeneic Breast Cancer Cell Line to Vaccinate HLA-A2-Positive Women With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Providence Cancer Center, Earle A. Chiles Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from breast cancer cells may make the body build an immune response&#xD;
      to kill tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of vaccines made from breast cancer cells&#xD;
      in treating women with metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and toxicity of vaccination strategies employing a CD80-transfected&#xD;
           allogeneic breast cancer cell line (MDA-MB-231).&#xD;
&#xD;
        -  Assess the immunologic response of lymphocytes isolated from lymph nodes draining the&#xD;
           vaccination site following a single dose of CD80-transfected MDA-MB-231.&#xD;
&#xD;
        -  Assess the development of systemic immunity following multiple injections of&#xD;
           CD80-transfected MDA-MB-231.&#xD;
&#xD;
        -  Observe for tumor regression.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive intradermal vaccinations containing CD80-transfected cells with or without&#xD;
      sargramostim (GM-CSF) or with or without BCG. Vaccinations are administered every 2 weeks for&#xD;
      6 weeks and then monthly for 3 months. Patients may receive 1 of 2 different doses of GM-CSF.&#xD;
      GM-CSF is administered with the vaccination, then every 12 hours for 7 days. Monthly&#xD;
      vaccinations may continue as long as response is shown.&#xD;
&#xD;
      Cohorts of 5 patients each are treated at each dose/combination. Each cohort completes&#xD;
      treatment before the next cohort is accrued.&#xD;
&#xD;
      Patients are followed at weeks 4 and 8, then every 2 months for 6 months, then every 3 months&#xD;
      for 1 year, and then every 6 months until disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 35 patients will be accrued for this study within 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1996</start_date>
  <completion_date type="Actual">July 2003</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCG vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD80 breast cancer vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven metastatic breast cancer&#xD;
&#xD;
               -  Stage IV disease patients who have either been treated to maximal response or who&#xD;
                  have had high dose chemotherapy or a marrow ablative regimen (if they meet&#xD;
                  immunologic criteria and have not received more than 2 chemotherapy regimens for&#xD;
                  treatment of metastatic disease)&#xD;
&#xD;
               -  Patients with advanced stage disease who:&#xD;
&#xD;
                    -  Received at least 1 standard chemotherapy regimen, but no more than 2, for&#xD;
                       treatment of metastatic disease&#xD;
&#xD;
                    -  Refused chemotherapy&#xD;
&#xD;
                    -  Refused or progressed despite hormonal therapy&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Positive or negative for HLA-A2&#xD;
&#xD;
          -  Must have superficial inguinal or axillary lymph nodes that are free of tumor&#xD;
             involvement and are surgically accessible&#xD;
&#xD;
          -  No symptomatic or acutely life threatening tumor that is judged likely to require&#xD;
             intervention with alternative modalities within 3 months&#xD;
&#xD;
          -  No brain metastases&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0 or 1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC greater than 3,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  BUN less than 25 mg/dL&#xD;
&#xD;
          -  Creatinine less than 1.8 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No ischemic or congestive cardiac disease requiring chronic medication&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  No evidence of ischemic change or ventricular ectopy (greater than 4/min) on&#xD;
             electrocardiogram (EKG)&#xD;
&#xD;
          -  No evidence of type II arterial-ventricular block&#xD;
&#xD;
          -  No evidence of current cardiac disease by stress test and EKG&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active infection requiring treatment&#xD;
&#xD;
          -  No psychiatric illness&#xD;
&#xD;
          -  No history of seizure disorder&#xD;
&#xD;
          -  No other prior malignancy within the past 10 years except squamous cell or basal cell&#xD;
             skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior specific or nonspecific immunotherapy, unless there is&#xD;
             obvious progression of metastatic disease, and recovered&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy, unless there is obvious progression of&#xD;
             metastatic disease, and recovered&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior steroids, unless there is obvious progression of&#xD;
             metastatic disease, and recovered&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Concurrent radiotherapy allowed for local control of disease&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter J. Urba, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Providence Cancer Center, Earle A. Chiles Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Earle A. Chiles Research Institute at Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213-2967</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Schoof DD, Smith JW 2nd, Disis ML, Brant-Zawadski P, Wood W, Doran T, Johnson E, Urba WJ. Immunization of metastatic breast cancer patients with CD80-modified breast cancer cells and GM-CSF. Adv Exp Med Biol. 1998;451:511-8. doi: 10.1007/978-1-4615-5357-1_79. No abstract available.</citation>
    <PMID>10026920</PMID>
  </results_reference>
  <verification_date>November 2000</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>July 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2003</study_first_posted>
  <last_update_submitted>April 2, 2013</last_update_submitted>
  <last_update_submitted_qc>April 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2013</last_update_posted>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>BCG Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

